Ingevity Highlights Significant Momentum on Actions Underway to Drive Improved Performance and Value Creation
Ingevity (NYSE: NGVT) has highlighted significant progress in its strategic initiatives to enhance business performance. The company achieved record performance in its Performance Materials division, with margins exceeding 50% in 2024, driven by new pricing and operational efficiency initiatives.
The company's Performance Chemicals segment transformation delivered $84 million in savings in 2024, surpassing their $65-75 million target. They expect additional savings of $10-25 million in 2025. Second-half EBITDA margins increased to approximately 28%, with improved free cash flow.
Ingevity announced a strategic alternatives review for their Industrial Specialties product line and North Charleston CTO refinery, expecting to communicate decisions by year-end. The company targets $400-415 million in EBITDA for 2025 and aims to reduce net leverage ratio below 2.8x by year-end 2025.
Ingevity (NYSE: NGVT) ha messo in evidenza progressi significativi nelle sue iniziative strategiche per migliorare le performance aziendali. L'azienda ha registrato un risultato record nella sua divisione Performance Materials, con margini superiori al 50% nel 2024, grazie a nuove iniziative di pricing e efficienza operativa.
La trasformazione del segmento Performance Chemicals ha generato risparmi per 84 milioni di dollari nel 2024, superando il target di 65-75 milioni di dollari. Si aspettano ulteriori risparmi di 10-25 milioni di dollari nel 2025. I margini EBITDA del secondo semestre sono aumentati a circa il 28%, con un miglioramento del flusso di cassa libero.
Ingevity ha annunciato una revisione delle alternative strategiche per la sua linea di prodotti Industrial Specialties e la raffineria CTO di North Charleston, prevedendo di comunicare le decisioni entro la fine dell'anno. L'azienda punta a 400-415 milioni di dollari in EBITDA per il 2025 e mira a ridurre il rapporto di leva netta al di sotto di 2,8x entro la fine del 2025.
Ingevity (NYSE: NGVT) ha destacado avances significativos en sus iniciativas estratégicas para mejorar el rendimiento empresarial. La compañía logró un rendimiento récord en su división de Materiales de Rendimiento, con márgenes superiores al 50% en 2024, impulsados por nuevas iniciativas de precios y eficiencia operativa.
La transformación del segmento de Químicos de Rendimiento generó ahorros de 84 millones de dólares en 2024, superando su objetivo de 65-75 millones de dólares. Esperan ahorros adicionales de 10-25 millones de dólares en 2025. Los márgenes EBITDA del segundo semestre aumentaron a aproximadamente el 28%, con una mejora en el flujo de caja libre.
Ingevity anunció una revisión de alternativas estratégicas para su línea de productos Especialidades Industriales y la refinería CTO de North Charleston, esperando comunicar decisiones para finales de año. La compañía tiene como objetivo 400-415 millones de dólares en EBITDA para 2025 y pretende reducir la relación de apalancamiento neto por debajo de 2.8x para finales de 2025.
인제비티 (NYSE: NGVT)는 비즈니스 성과를 향상시키기 위한 전략적 이니셔티브에서 중요한 진전을 강조했습니다. 이 회사는 성능 소재 부문에서 기록적인 성과를 달성했으며, 2024년에는 50% 이상의 마진을 기록했습니다. 이는 새로운 가격 책정 및 운영 효율성 이니셔티브에 의해 촉진되었습니다.
회사의 성능 화학 부문 변환은 2024년에 8400만 달러의 절감을 가져왔으며, 그들의 6500만-7500만 달러 목표를 초과 달성했습니다. 그들은 2025년에 추가로 1000만-2500만 달러의 절감을 예상하고 있습니다. 하반기 EBITDA 마진은 약 28%로 증가했으며, 자유 현금 흐름이 개선되었습니다.
인제비티는 산업 특수 제품 라인과 노스 찰스턴 CTO 정유소에 대한 전략적 대안 검토를 발표했으며, 연말까지 결정을 통보할 예정입니다. 회사는 2025년 EBITDA 4억-4억 1500만 달러를 목표로 하고 있으며, 2025년 말까지 순 레버리지 비율을 2.8배 이하로 줄이는 것을 목표로 하고 있습니다.
Ingevity (NYSE: NGVT) a mis en avant des progrès significatifs dans ses initiatives stratégiques pour améliorer la performance de l'entreprise. La société a atteint une performance record dans sa division Performance Materials, avec des marges dépassant 50 % en 2024, soutenues par de nouvelles initiatives de tarification et d'efficacité opérationnelle.
La transformation du segment Performance Chemicals a permis d'économiser 84 millions de dollars en 2024, dépassant leur objectif de 65-75 millions de dollars. Ils s'attendent à des économies supplémentaires de 10-25 millions de dollars en 2025. Les marges EBITDA du second semestre ont augmenté à environ 28 %, avec une amélioration du flux de trésorerie libre.
Ingevity a annoncé un examen des alternatives stratégiques pour sa gamme de produits Industrial Specialties et la raffinerie CTO de North Charleston, prévoyant de communiquer les décisions d'ici la fin de l'année. L'entreprise vise 400-415 millions de dollars d'EBITDA pour 2025 et vise à réduire le ratio d'endettement net en dessous de 2,8x d'ici la fin de 2025.
Ingevity (NYSE: NGVT) hat bedeutende Fortschritte bei seinen strategischen Initiativen zur Verbesserung der Unternehmensleistung hervorgehoben. Das Unternehmen erzielte rekordverdächtige Ergebnisse in seiner Performance Materials-Sparte, mit Margen von über 50% im Jahr 2024, angetrieben von neuen Preis- und Effizienzinitiativen.
Die Transformation des Segments Performance Chemicals brachte 84 Millionen Dollar Einsparungen im Jahr 2024, was das Ziel von 65-75 Millionen Dollar übertraf. Für 2025 erwarten sie zusätzliche Einsparungen von 10-25 Millionen Dollar. Die EBITDA-Margen in der zweiten Jahreshälfte stiegen auf etwa 28%, mit verbessertem freien Cashflow.
Ingevity kündigte eine Überprüfung strategischer Alternativen für ihre Produktlinie Industrial Specialties und die Raffinerie CTO in North Charleston an und erwartet, bis Ende des Jahres Entscheidungen zu kommunizieren. Das Unternehmen strebt 400-415 Millionen Dollar EBITDA für 2025 an und zielt darauf ab, das Netto-Verschuldungsverhältnis bis Ende 2025 unter 2,8x zu senken.
- Record Performance Materials results with margins over 50%
- $84M cost savings achieved in 2024, exceeding $65-75M target
- EBITDA margins increased to 28% in H2 2024
- Significant free cash flow improvement
- Additional $10-25M savings expected in 2025
- Challenging market backdrop acknowledged
- Ongoing debt reduction needed to reach leverage target
- CEO position currently vacant
Insights
Ingevity's shareholder letter reveals a company actively restructuring to improve profitability while fending off an activist challenge from Vision One. The most significant developments include the record performance in the Performance Materials segment with margins exceeding
The financial metrics show encouraging momentum with second-half 2024 EBITDA margins reaching approximately
The timing of Vision One's involvement is noteworthy - they approached Ingevity after the company had already initiated its portfolio review and CEO transition, suggesting the activist may be attempting to claim credit for changes already underway. The board's rejection of Vision One's nominees citing their lack of relevant experience appears reasonable, though the standoff creates uncertainty.
For investors, this situation presents both opportunity and risk. The operational improvements and portfolio rationalization could unlock significant value if executed properly. However, the CEO transition and potential distraction from the proxy fight might delay implementation of these initiatives. The rejection of compromise with Vision One could also lead to a protracted and potentially disruptive proxy battle.
The strategic alternatives process for Industrial Specialties will be particularly important to watch, as successful divestiture could accelerate debt reduction and allow management to focus on higher-margin segments. Overall, Ingevity appears to be making the right strategic moves, but execution and the resolution of the activist situation will determine whether these initiatives translate into sustainable shareholder value.
Ingevity's strategic repositioning represents a calculated response to both operational challenges and activist pressure. The company's three-part strategy - optimizing Performance Materials, transforming Performance Chemicals, and reviewing the broader portfolio - addresses key value creation levers, but execution risks remain substantial.
The Performance Materials success with
The Performance Chemicals transformation has delivered meaningful results with
The timing of these initiatives relative to Vision One's involvement suggests management was already moving in the right direction, though perhaps not at the pace some investors desired. The debt reduction target of 2.8x leverage by year-end 2025 is modest compared to specialty chemical peers who typically target 1.5-2.5x, suggesting more aggressive deleveraging may be warranted.
The ongoing CEO search represents both the greatest risk and opportunity. The right leader could accelerate these initiatives, while a poor selection could derail progress. Vision One's push for board representation during this transition creates additional uncertainty.
For investors, Ingevity presents a potential turnaround story with clear catalysts: portfolio optimization, margin expansion, and cash flow improvement. However, the activist situation adds complexity to the investment thesis. The company's willingness to make significant changes suggests management recognizes the need for transformation, but the question remains whether these changes will be sufficient to drive sustainable outperformance in an increasingly challenging specialty chemicals landscape.
Delivered Record Year in Performance Materials and Strategic Repositioning in Performance Chemicals Is Already Demonstrating Results
Business Portfolio Review Is Progressing with Recently Announced Strategic Alternatives Process for Industrial Specialties Product Line and Evaluation of Additional Portfolio and Cost Reduction Actions Ongoing
Provides Information About Engagement with Vision One
Dear Ingevity Stockholders,
The Ingevity Board of Directors and leadership team are committed to taking aggressive actions to deliver significant, sustainable value creation for all Ingevity stockholders. Over the last year, we have undertaken a broad range of initiatives to enhance our business performance, improve our portfolio and strengthen our governance. These initiatives include:
-
Delivering a record year for Performance Materials. In 2024, we delivered record performance for our Performance Materials business for both sales and EBITDA, with margins surpassing
50% , driven by new pricing and operational efficiency initiatives. We expect continued momentum in this business as we see ICE vehicles continue to become more fuel efficient, as well as consumer preferences trending toward hybrids. We are also making progress in developing new markets for our carbon technologies in silicon anode batteries through our investment in Nexeon.
- Transforming our Performance Chemicals segment. We have made significant progress proactively managing our Performance Chemicals business, exiting lower margin, cyclical end markets, reducing our physical footprint to optimize costs and diversifying our raw material streams. In addition, we have addressed uneconomic long-term supply contracts, enhancing our ability to better manage the cost and timing of key raw material purchases.
- Reviewing our portfolio, including a formal process for our Industrial Specialties product line and North Charleston CTO refinery. On October 30, 2024, we publicly announced that we were reviewing our business portfolio, a review which began in March 2024. As part of this review, we announced on January 16, 2025, a formal exploration of strategic alternatives for the majority of the Industrial Specialties product line and our North Charleston CTO refinery. We expect that exiting this product line will further strengthen the Performance Chemicals segment and enable us to focus our attention on higher growth and higher margin opportunities within our portfolio while improving the company’s earnings and cash flow profile. We are proceeding expeditiously with the review of Industrial Specialties and the refinery and expect to communicate a path forward by year end. We are also continuing to review the rest of our portfolio.
- Continuing to enhance our Board with fresh, qualified perspectives. In June 2024, as part of our ongoing board refreshment process, we began a search for a new director with the assistance of an independent search firm. This search culminated in the appointment of J. Kevin Willis, Senior Vice President & Chief Financial Officer of Ashland Inc., to our Board in December 2024. Mr. Willis played an integral role in Ashland’s successful separation from Valvoline and the reorganization of Ashland’s European operations. With Mr. Willis’s appointment, Ingevity has now added three new independent directors over the last three years.
Despite a challenging market backdrop, these initiatives are already delivering results. In addition to our record results in Performance Materials, we realized
It is important to emphasize that in addition to the meaningful actions already underway, the Company is continuing to evaluate additional opportunities to further reduce costs, as well as reviewing our portfolio with a “best owner” mindset. The CEO search is progressing well and we are very pleased with the quality of the candidates under consideration.
Background on Engagement with Vision One
As you have likely seen, one of our recent stockholders, Vision One, today issued a public presentation outlining their perspectives on the Company and making specific demands regarding our portfolio and governance.
Vision One first approached the Company in November 2024 – well after we initiated a search for new directors and announced our CEO transition and new strategic priorities, including our portfolio review. Since first being made aware of their concerns through a letter to our Board, members of Ingevity’s Board and management team have met with Vision One’s principals to hear their views on the Company, with the goal of developing a constructive dialogue on how to deliver more stockholder value.
In January, Vision One formally nominated four director candidates, including Vision One principals Courtney Mather and Julio Acero, along with two other candidates, Merri Sanchez and F. David Segal. Our Nominating and Governance Committee carefully considered and interviewed each of the nominees pursuant to our established process. At the conclusion of that process, the Nominating and Governance Committee ultimately decided not to recommend any of the candidates to the Board.
In coming to its conclusion, the Committee determined that each of Vision One’s candidates lacked relevant sector or public company executive experience and would not meaningfully improve the mix of operational, portfolio or capital allocation expertise on the Board, which are areas of expertise that the Board believes are priorities given the Company’s ongoing evaluation of operational improvements and the review of the Company’s portfolio.
In an effort to advance a constructive resolution with Vision One, we offered to work collaboratively with Vision One to identify a mutually agreed director candidate that had expertise aligned with the needs of the Company and our strategy at this time. We also invited them to present their perspectives to the Board, in an effort to deepen our engagement and dialogue.
However, with Ingevity in the midst of a CEO transition and an active strategic review process, Vision One has rejected our efforts to engage constructively and has been focused on adding their four hand-picked representatives to the Board. It has now launched a proxy contest to further this objective. While the Company remains open to engagement with Vision One, we do not believe that Vision One’s candidates are additive to our Board and do not believe that their election would be in the best interests of the Company. The Ingevity Board remains open to resolving this matter constructively with Vision One – but will only do so in a manner that serves the best interest of all Ingevity stockholders.
We look forward to engaging with our stockholders over the coming weeks to hear your perspectives, and we thank you for your continued investment in and support of Ingevity.
The Ingevity Board and its Nominating and Governance Committee will present its formal recommendation regarding the election of directors in the Company’s proxy statement and other materials, to be filed with the Securities and Exchange Commission and mailed to all stockholders eligible to vote at the Annual Meeting. Stockholders are not required to take any action at this time.
Ingevity: Purify, Protect and Enhance
Ingevity provides products and technologies that purify, protect and enhance the world around us. Through a team of talented and experienced people, we develop, manufacture and bring to market solutions that help customers solve complex problems and make the world more sustainable. We operate in three reporting segments: Performance Materials, which includes activated carbon; Advanced Polymer Technologies, which includes caprolactone polymers; and Performance Chemicals, which includes specialty chemicals and road technologies. Our products are used in a variety of demanding applications, including agrochemicals, asphalt paving, certified biodegradable bioplastics, coatings, elastomers, pavement markings and automotive components. Headquartered in
Use of non-GAAP financial measures: This press release includes certain non-GAAP financial measures intended to supplement, not substitute for, comparable GAAP measures. Reconciliations of non-GAAP financial measures to GAAP financial measures are provided within the Appendix to this press release. Investors are urged to consider carefully the comparable GAAP measures and the reconciliations to those measures provided. The company does not attempt to provide reconciliations of forward-looking non-GAAP guidance to the comparable GAAP measure because the impact and timing of the factors underlying the guidance assumptions are inherently uncertain and difficult to predict and are unavailable without unreasonable efforts. In addition, Ingevity believes such reconciliations would imply a degree of certainty that could be confusing to investors.
Forward-looking statements: This press release contains “forward looking statements” within the meaning of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Such statements generally include the words “will,” “plans,” “intends,” “targets,” “expects,” “outlook,” “guidance,” “believes,” “anticipates” or similar expressions. Forward looking statements may include, without limitation, anticipated timing, results, charges and costs of any current or future repositioning of our Performance Chemicals segment, including the announced review of strategic alternatives for the Industrial Specialties product line and
Important Additional Information Regarding Proxy Solicitation: Ingevity intends to file a proxy statement and WHITE proxy card with the SEC in connection with the solicitation of proxies for Ingevity’s 2025 annual meeting of stockholders (the “Proxy Statement” and such meeting the “2025 Annual Meeting”). Ingevity, its directors and certain of its executive officers may be deemed to be participants in the solicitation of proxies from stockholders in respect of the 2025 Annual Meeting. Additional information regarding the identity of these potential participants and their respective interests in Ingevity by security holdings or otherwise will be set forth in the Proxy Statement and other materials to be filed with the SEC in connection with the 2025 Annual Meeting. Information relating to the foregoing can also be found in Ingevity’s definitive proxy statement for its 2024 annual meeting of stockholders, filed with the SEC on March 11, 2024 (the “2024 Proxy Statement”). Please refer to the sections captioned “Ownership of Equity Securities,” “Director Compensation,” “Compensation Discussion and Analysis” and “Compensation Tables and Other Matters” in the 2024 Proxy Statement. To the extent the holdings of such participants in Ingevity’s securities have changed since the amounts described in the 2024 Proxy Statement, such changes have been reflected on Initial Statements of Beneficial Ownership on Form 3 or Statements of Change in Ownership on Form 4 filed with the SEC, including: Forms 4 filed by Mary Dean Hall on April 23, 2024 and February 21, 2025; Form 4 filed by Steve Hulme on February 21, 2025; Form 4 filed by Ed Woodcock on February 21, 2025; Form 4 filed by Benjamin (Shon) Wright on April 26, 2024; Form 4 filed by Dan Sansone on April 26, 2024; Form 4 filed by Karen Narwold on April 26, 2024; Form 4 filed by Fred Lynch on April 26, 2024; Form 4 filed by Bruce Hoechner on April 26, 2024; Form 4 filed by Diane Gulyas on April 26, 2024; Form 4 filed by Jean Blackwell on April 26, 2024; Forms 4 filed by Rich White on July 3, 2024 and February 21, 2025; Form 3 filed by Ryan Fisher on April 8, 2024 and Forms 4 filed by Ryan Fisher on May 7, 2024, July 8, 2024 and February 21, 2025; Forms 4 filed by Phillip Platt on August 13, 2024 and February 21, 2025; Form 4 filed by Terry Dyer on August 13, 2024; Forms 4 filed by Luis Fernandez-Moreno on April 26, 2024 and October 4, 2024; and Form 3 filed by Kevin Willis on December 19, 2024 and Forms 4 filed by Kevin Willis on December 19, 2024 and January 3, 2025. Additional information can also be found in Ingevity’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on February 19, 2025. Details concerning the nominees of Ingevity’s Board of Directors for election at the 2025 Annual Meeting will be included in the Proxy Statement. BEFORE MAKING ANY VOTING DECISION, INVESTORS AND STOCKHOLDERS ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH OR FURNISHED TO THE SEC, INCLUDING INGEVITY’S PROXY STATEMENT WHEN IT BECOMES AVAILABLE (AND ANY AMENDMENTS AND SUPPLEMENTS THERETO) CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. These documents, including the Proxy Statement (and any amendments or supplements thereto) and other documents filed by Ingevity with the SEC, are available free of charge at the SEC’s website at http://www.sec.gov and at Ingevity’s investor relations website at http://ir.ingevity.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250225540940/en/
Media:
Caroline Monahan
843-740-2068
media@ingevity.com
Kara Brickman / Greg Klassen
Joele Frank, Wilkinson Brimmer Katcher
212-355-4449
Investors:
John E. Nypaver, Jr.
843-740-2002
investors@ingevity.com
Source: Ingevity Corporation